Kimberly Kruczek, DO
Hematology & Oncology · Flossmoor, ILNPI 1346569563
Payments from drug & device makers
Across 201 payments — averaging $1013.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$93K
- Pfizer$38K
- Seagen Inc.$21K
- Global Blood Therapeutics, Inc.$13K
- Roche TCRC, Inc.$12K
- AbbVie$9K
- plus $19K from 28 others
Across 1 payment — averaging $2250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2K
What the payments were for
- Consulting fees$4,2704%
- Speaking & faculty fees$91,73077%
- Travel & lodging$18,89316%
- Food & beverage$4,6004%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 73 | $92,592 |
| Pfizer | 15 | $38,033 |
| Seagen Inc. | 4 | $20,811 |
| Global Blood Therapeutics, Inc. | 13 | $12,650 |
| Roche TCRC, Inc. | 3 | $12,143 |
| AbbVie | 8 | $8,595 |
| Genentech, Inc. | 2 | $6,745 |
| Sobi, Inc | 3 | $4,521 |
| Dova Pharmaceuticals | 1 | $3,000 |
| Verastem, Inc. | 1 | $2,000 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $1,000 |
| Novartis | 18 | $369 |
| AstraZeneca | 15 | $284 |
| Bristol Myers Squibb | 9 | $198 |
| GE HealthCare | 1 | $135 |
| E.r. Squibb & Sons, L.L.C. | 6 | $114 |
| Genentech USA, Inc. | 3 | $69 |
| Cardinal Health 414 LLC | 3 | $62 |
| EMD Serono, Inc. | 2 | $56 |
| Johnson & Johnson(2 entities) | 3 | $51 |
| Daiichi Sankyo Inc. | 2 | $47 |
| Merck | 2 | $46 |
| Beone Medicines USA, Inc. | 1 | $30 |
| Sanofi | 1 | $29 |
| Deciphera Pharmaceuticals Inc. | 1 | $26 |
| Incyte Corporation | 1 | $25 |
| Myriad Genetic Laboratories, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $25 |
| EUSA Pharma (US) LLC | 1 | $25 |
| G1 Therapeutics, Inc. | 1 | $24 |
| Tempus AI, Inc | 1 | $22 |
| Puma Biotechnology, Inc. | 1 | $21 |
| Amgen | 1 | $15 |
| Rigel Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Trodelvy$91,415
- Non-Covered Product$12,143
- OXBRYTA$11,788
How this compares
$203,804 in reported general payments places this provider in the 75th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 45 | $633,839 |
| ImbruvicaIbrutinib | 23 | $325,702 |
| RevlimidLenalidomide | 19 | $307,352 |
| IbrancePalbociclib | 14 | $198,776 |
| CalquenceAcalabrutinib Maleate | 11 | $151,787 |
| EliquisApixaban | 141 | $140,396 |
| Abiraterone Acetate | 21 | $41,692 |
| XareltoRivaroxaban | 31 | $28,327 |
| Letrozole | 143 | $3,371 |
| Imatinib Mesylate | 12 | $2,202 |
| Hydroxyurea | 15 | $751 |
| Anastrozole | 32 | $648 |
| Ondansetron Hcl | 47 | $527 |
| Acyclovir | 33 | $473 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 30 | $282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $38,033 | $339,172155 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $1,000 | $325,70223 claims |
| Bristol Myers SquibbRevlimid | $198 | $307,35219 claims |
| AstraZenecaCalquence | $284 | $151,78711 claims |
| Johnson & JohnsonXarelto | $51 | $28,32731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 580 hematology & oncology providers in Illinois.
Other hematology & oncology in Flossmoor
- Richard SchilskyBurr Ridge$87.1M
- Edwin PosadasBurr Ridge$70.9M
- Oana DanciuChicago$23.2M
- Shuo MaChicago$20.5M
- Olwen HahnChicago$11.9M
- Christine BestvinaChicago$11.3M
- Russell SzmulewitzChicago$9.8M
- Randy SweisChicago$9.4M
- Hedy KindlerChicago$8.6M
- Reem KarmaliChicago$7.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.